Medical Oncology

Transplant nephrology

Questions discussed in this category

How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?

Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.

1 Answer available

Would you consider a BRCA carrier patient for kidney transplantation?

5 Answers available

What is your strategy for managing immunosuppression in patients with a kidney transplant who develop metastatic cancer?

3 Answers available

Would you consider clearing a patient with essential thrombocytosis for a kidney donation?

1 Answer available

Papers discussed in this category

Transplantation reviews (Orlando, Fla.), 2021 Jun 24

Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference.

Oncology research, 2018-04-10

Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis.

Balkan journal of medical genetics : BJMG, 2023 May 02

Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers.

Kidney international, 2018-07

Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.

BMC nephrology, 2019-02-14

Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.

Related Topics in Medical Oncology